Meta-analysis confirms teprotumumab benefits and side effects in thyroid eye disease

A systematic review and meta-analysis pooled 6 randomized controlled trials and 30 real-world studies of intravenous teprotumumab for thyroid eye disease. The analysis reported that teprotumumab improved proptosis (risk ratio 4.55 in RCTs; 82% response in real-world studies) and diplopia (risk ratio 2.13 in RCTs; 60% response in real-world studies), while hyperglycemia (risk ratio 2.67; 17% in real-world studies) and hearing impairment (risk ratio 4.05; 18% in real-world studies) were more frequent with treatment. The authors concluded these real-world safety findings warrant appropriate patient selection and monitoring.

Most relevant for: Adults with moderate-to-severe thyroid eye disease being considered for or treated with teprotumumab.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.